193 related articles for article (PubMed ID: 10030500)
1. Rules set for dissemination of off-label-use information.
Miller JL
Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
[No Abstract] [Full Text] [Related]
2. What drug labels don't tell you.
Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
[No Abstract] [Full Text] [Related]
3. FDA off-track on off-label drug promotion.
Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
[No Abstract] [Full Text] [Related]
4. Stoning a dead bird: advertising limits on approved new drugs.
Strobos J
Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
[No Abstract] [Full Text] [Related]
5. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
Weeks EA
Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
[No Abstract] [Full Text] [Related]
6. Regulation of pharmacoeconomics and outcomes research.
Radensky P
Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
[No Abstract] [Full Text] [Related]
7. MedGuide: at last a long-sought opportunity for patient education about prescription drugs.
Marwick C
JAMA; 1997 Mar; 277(12):949-50. PubMed ID: 9091654
[No Abstract] [Full Text] [Related]
8. Information on marketed drugs for doctors and patients. Experience in six European countries.
Brown P; Charlish P; Brazier H; Butterfield M
Int J Technol Assess Health Care; 1995; 11(3):410-6. PubMed ID: 7591543
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
Strawn MN
J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
[No Abstract] [Full Text] [Related]
10. Regulating off-label drug use--rethinking the role of the FDA.
Stafford RS
N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
[No Abstract] [Full Text] [Related]
11. FDA advisers support rescheduling of hydrocodone products.
Traynor K
Am J Health Syst Pharm; 2013 Mar; 70(5):383-4. PubMed ID: 23413158
[No Abstract] [Full Text] [Related]
12. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
Mackey TK; Liang BA
Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416
[No Abstract] [Full Text] [Related]
13. Forbidden and Permitted Statements about Medications--Loosening the Rules.
Avorn J; Sarpatwari A; Kesselheim AS
N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
[No Abstract] [Full Text] [Related]
14. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
Leghorn J; Brophy E; Rother P
Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
[No Abstract] [Full Text] [Related]
15. The new FDA pregnancy labeling requirements for drugs.
Frederiksen MC
J Midwifery Womens Health; 2011; 56(3):303-7. PubMed ID: 21535377
[TBL] [Abstract][Full Text] [Related]
16. Lessons from cisapride.
CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
[No Abstract] [Full Text] [Related]
17. Judge strikes down FDA policies on industry dissemination of off-label information.
Miller JL
Am J Health Syst Pharm; 1999 Sep; 56(17):1695-6. PubMed ID: 10512492
[No Abstract] [Full Text] [Related]
18. Proposed legislation--its impact on drug information processing.
Cleveland CB; Adams J
Drug Inf J; 1978; 12(3):181-4. PubMed ID: 10239117
[No Abstract] [Full Text] [Related]
19. Data sheets: a consumer perspective.
Medawar C
Lancet; 1988 Apr; 1(8588):777-8. PubMed ID: 2895311
[No Abstract] [Full Text] [Related]
20. Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries.
Hallersten A; Fürst W; Mezzasalma R
Regul Toxicol Pharmacol; 2016 Jun; 77():275-81. PubMed ID: 27041395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
